Protocol Number: 04-C-0102

Title:

Hematologic Malignancy Biology Study

Number:

04-C-0102

Summary:

This study will collect tumor samples from people with cancers of the blood, bone marrow, or lymph glands for laboratory study of the biology of these conditions. Such studies contribute to a better understanding of cancer biology and to the development of new treatments. Planned studies include:

- Examination of individual cancer cells and to search for differences compared to other types of cancer and normal cells

- Examination of the chromosomes and genes in cancer cells and to search for differences compared to other types of cancer and normal cells

- Development of sensitive methods to detect small amounts of cancer that remain after treatment

- Search for new cancer proteins that might serve as targets for treatment

- Investigation of methods to develop cancer vaccines.

Patients from birth to 75 years of age with acute lymphocytic leukemia, acute myelogenous leukemia, myelodysplastic syndrome, chronic myelogenous leukemia, juvenile myelomonocytic leukemia, non-Hodgkin's lymphoma, Hodgkin's disease, and other hematologic malignancies may be eligible for this study.

Blood or bone marrow samples will be collected when sampling is required for the patient's medical care. Cells from some individuals will be grown in test tubes, establishing cell lines or in animals, establishing xenograft models. (A xenograft is transplantation of cells of one species to another species.)

Sponsoring Institute:

National Cancer Institute (NCI)

Recruitment Detail

Type: Participants currently recruited/enrolled

Gender: Male & Female

Referral Letter Required: Yes

Population Exclusion(s): None

Eligibility Criteria:

INCLUSION CRITERIA

Diagnosis of any hematologic malignancy or pre-malignant blood disorder, including but not restricted to the following:

Acute Lymphocytic Leukemia (ALL)

Acute Myelogenous Leukemia (AML)

Myelodysplastic Syndrome (MDS)

Chronic Myelogenous Leukemia (CML)

Juvenile Myelomonocytic Leukemia (JMML, J-CML)

Non-Hodgkin's Lymphoma (NHL)

Hodgkin's Disease

Tumor tissue that has been previously collected and is available for study or that can be collected with minimal additional risk to the subject during sampling required for routine patient care.

Patient age: birth to 75 years.

Prior therapy: no restrictions

Informed consent or IRB waiver of the requirement for informed consent for specific research studies.

EXCLUSION CRITERIA

None

Special Instructions:

Currently Not Provided

Keywords:

Leukemia

Biology Study

Lymphoma

Myelodysplastic Syndrome

Recruitment Keyword(s):

None

Condition(s):

Hematologic Malignancy

Investigational Drug(s):

None

Investigational Device(s):

None

Intervention(s):

None

Supporting Site:

National Cancer Institute

Contact(s):

NCI Referral Office
National Institute of Health Clinical Center (CC), 9000 Rockville Pike, Bethesda, Maryland 20892, United States: NCI Clinical Trials Referral Office
Phone: 1-888-NCI-1937
Fax: Not Listed
Electronic Address: ncicssc@mail.nih.gov

Citation(s):

Szczepanski T, Willemse MJ, Brinkhof B, van Wering ER, van der Burg M, van Dongen JJ. Comparative analysis of Ig and TCR gene rearrangements at diagnosis and at relapse of childhood precursor-B-ALL provides improved strategies for selection of stable PCR targets for monitoring of minimal residual disease. Blood. 2002 Apr 1; 99(7): 2315-23.

van der Velden VH, Jacobs DC, Wijkhuijs AJ, Comans-Bitter WM, Willemse MJ, Hahlen K, Kamps WA, van Wering ER, van Dongen JJ. Minimal residual disease levels in bone marrow and peripheral blood are comparable in children with T cell acute lymphoblastic leukemia (ALL), but not in precursor-B-ALL. Leukemia. 2002 Aug; 16(8): 1432-6.

Menssen HD, Renkl HJ, Rodeck U, Maurer J, Notter M, Schwartz S, Reinhardt R, Thiel E. Presence of Wilms' tumor gene (wt1) transcripts and the WT1 nuclear protein in the majority of human acute leukemias. Leukemia. 1995 Jun; 9(6): 1060-7.

• Questions about participating in a study, please contact the Patient Recruitment and Public Liaison Office, CC.
• Technical questions regarding the Clinical Center web site, please contact the Department of Clinical Research Informatics, CC.

Search The Studies | Help | Questions |
Clinical Center Home | NIH Home

National Institutes of Health Clinical Center Bethesda, Maryland 20892. Last update: 05/05/2009